August 16, 2024
2 minute read
Important points:
- Most respondents to a small survey said they followed the ADA's recommendations for screening for type 1 diabetes.
- One-third of respondents said they had no knowledge about the use of teplizumab to delay type 1 diabetes.
Presenters said most diabetes care and education professionals believe presymptomatic screening for type 1 diabetes is important, but some have limited knowledge about teplizumab-mzwv. said.
Researchers presented the results of a small cross-sectional study focused on type 1 diabetes screening and prevention at the annual meeting of the Association of Diabetes Care Educators. Most respondents were neutral or agreed with the American Diabetes Association's 2024 Standard of Care Recommendations for staging and screening for type 1 diabetes, and the majority were knowledgeable about teplizumab-mzwv (Tzield, Prevention Bio). We agreed on one thing. but, Jennifer Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM, A clinical professor and director of pharmaceutical education at the University of South Carolina College of Pharmacy said some respondents were unsure about using teplizumab-mzwv, leading to low response rates to the survey.
“I think it would be great to get a more real-world perspective on teplizumab,” Clements told Healio. “As individuals become more knowledgeable about drugs and perhaps gain clinical experience, it will be important to share best practices.”
jennifer clements
Diabetes care and education experts were invited to complete a 20-question survey regarding the role of teplizumab-mzwv in type 1 diabetes screening and staging and treatment of presymptomatic type 1 diabetes. Ta. The study was conducted over a six-week period. After participants filled out their demographic information, they responded to the statements on a 5-point Likert scale. The responses for each statement were “strongly disagree,” “disagree,” “neutral,” “agree,” and “strongly agree.”
Of the 21 diabetes care and education professionals who responded to the survey, 81% had 11 years or more of practice experience, and 61.9% worked in ambulatory care or ambulatory care. Of the respondents, 61.9% indicated that less than 25% of their patient population had type 1 diabetes. Twelve of the respondents indicated that 76% or more of their clinic's patient population was adults.
The majority of respondents were neutral, promoting screening for pre-existing type 1 diabetes, promoting staging of patients with type 1 diabetes based on characteristics and diagnostic criteria, and recommending patients with type 1 diabetes for further evaluation based on the following criteria: Agreed or strongly agreed to make a suggestion or referral to a specialized center. 2024 ADA Standards of Care. Eight respondents either disagreed or strongly opposed referring patients to specialized centers.
“It's encouraging that most respondents agree on the importance of type 1 diabetes screening,” Clements said. “The recommendations are clear and should be considered for implementation into clinical practice regardless of the setting.”
Among participants, 66.7% agreed or strongly agreed that there is knowledge to support the role of teplizumab-mzwv in delaying symptomatic type 1 diabetes, while 19% disagreed and 14.2% strongly disagreed. Responses were similar when participants were asked whether they had knowledge to promote the use of teplizumab-mzwv to delay type 1 diabetes in patients with stage 2 type 1 diabetes aged 8 years and older.
“Due to the small sample size, we cannot definitively determine whether respondents were familiar with teplizumab-mzwv,” Clements said. “However, there may be diabetes care and education professionals who do not have clinical experience with this drug based on clinical practice, patient population, or other reasons.”
The majority of respondents understood that 2 islet antibody positivity is required to prescribe teplizumab-mzwv, the need for a complete blood count and liver enzyme testing, and the dosing and cost of teplizumab-mzwv. Agree or strongly agree.
Clements said more information is needed to explain best practices for type 1 diabetes screening and use of teplizumab-mzwv.
collapse
Clements J et al. P-218. Presentation location: ADCES24; August 9-12, 2024. new orleans.
Disclosure: Clements, who works for Eli Lilly and Novo Nordisk's speaker bureaus, reports.
